Results:
The dose delivered to the PTVs was 67.9 Gy (range 66-70) 2.02 Gy/fr (1.9 -2.2) to PTV HR, 62.3 Gy (range 58-66) 1.86 Gy/fr (1.7-2) to PTV IR, 55.9 Gy (range 51-60) 1.68 Gy/fr (1.65-2) to PTV LR. The mean dose was 41.56 Gy (range 17.8 -66.8) to OP and 24.9 Gy (range 4.7-39.7) to CP; the external CP received 21.7 Gy mean dose. 36 (46.1%) patients experienced mouth dryness, thickened saliva and altered taste (31 G1 and 5 G2) during RT. At a median follow up of 24 months (range 6-56.2) 19 cases with xerostomia were recorded, 15 (19%) G1 and 4 (5,1%) G2. No G3 was observed. The symptom was recorded on an average of 8 months (range 6-15) after RT. Only 13/36 patients with acute salivary problems experienced late xerostomia.
Conclusion:
In our experience 25 Gy mean dose to the whole contra-lateral parotid, with <24 Gy mean dose to the external CP, even with sacrifice of the OP, allowed our patients to maintain an adequate salivation. 24% of cases experienced G1 and G2 xerostomia. No G3 toxicity was observed.
EP-1103
Review of thyroid ablation rates with RAI based on I131 uptake in differentiated thyroid carcinoma M. Keys Results: Of the cases analysed 73% were female and 27% male with a mean age of 44 years. The predominant histological subtype was papillary (73%), followed by follicular (22%). Most had early stage disease; Stage I (65%), Stage II (22%), Stage III (13%), 39 cases were pN0 and 29 had pN1 disease. Regarding surgery performed 39 patients had a complete excision CE, 22 had residual disease and there was no information for 7 cases. Thirty seven (37) cases had microscopically positive margins, 26 were negative and it was unknown in 5. Pre RAI ablation, Post op. RAI (I131) uptake in these patients was an average of 3.6 % in pN1 disease and 5.1% in those with pN0 disease. The max uptake was 28%. The extent of the surgery tended to influence the trend of uptake. There was a trend to a higher mean uptake in those who didn't have a CE with an uptake of 0.1-17%, and mean of 6.3%. Patients that had a CE had an uptake of 0-28%, and mean of 3.9%. In the SLRON there was no standard protocol for RAI dosage at the time the patients were treated The mean and range of doses of RAI administered was looked at based on pre-ablation uptake scans. Group 1 had a preablation uptake of <4% and group 2 >4%. For group 1 the mean dose was 3.9GBq with a range 2.2-7.4GBq, and group 2 had a mean of 3.7GBq with a range of 2.8-7.4GBq. Postablative RAI131 scans showed an average of 0.07% uptake with the majority of patients (33) having <0.1% uptake. At the time of analysis 23 patients remained disease free, 10 had metastases (M1) and 2 had died from metastatic disease.
Conclusion:
In those that received RAI ablation, high ablation rates ≥90% were shown despite variability in post -op. I131 uptake and dose of RAI administered. There didn't appear to be an association between those with recurrent or metastatic disease and their pre-ablation uptake rates, it was more associated with original stage. The aim of this prospective study is the comparison of perfusion parameters changes ( ∆CTPp) before and after radio-chemotherapy (RCT) and their correlation with maximum standard uptake values variations (∆SUV max) among patients (pts) with head and neck tumor (HNT), in order to evaluate the prognostic value of perfusion CT parameters (CTPp) in predicting response to RCT.
EP-1104 Role of perfusion CT in evaluation of tumour response after radiochemotherapy in H&N cancer

Material and Methods:
We enrolled pts with intermediate and advanced stage of HNT (stage III-IV), candidated to RCT with curative intent. All pts underwent to a pretreatment diagnostic and staging workup including perfusion CT (CTP) and FDG-PET/CT total body. Pts also perform a CTP 3 weeks after the end of RCT (CTP3w) and both CTP and PET/CT 3 months after the end of RCT (CTP3m and PET/CT repectively). We analised variations of following CTPp: Blood Flow (BF), Blood Volume (BV), Mean Transit Time (MTT) and Permeability-surface product (PS). All RCT treatments were performed using intensity modulated radiotherapy technique with simultaneous integrated boost. Prescribed doses were 66 Gy at 2.2 Gy per fraction to high risk volume PTV and 60-54 Gy at 2.0-1.8 Gy per fraction respectively to intermediate (optional) and low risk PTVs, delivered in 30 daily fractions. Concurrent weekly Cisplatin 40 mg/ m2 or Cisplatin 100 mg/m2 day 1, 22 an 43 was offered to all pts.
Results: From July 2012 to July 2015 25 pts affected by stage III/IV HNT candidate to RCT were enrolled in our study. FDG-PET/CT 3 months after the end of RCT showed a complete metabolic response in 16 pts (64%), a partial metabolic response in 7 pts (28%), a stable metabolic disease in 1 pts and progression metabolic disease in 1 pts (according PERCIS criteria). A significant reduction of all CTPp was observed from baseline CTP to CTP3w, except for MTT that did not show a significant variation (p= 0,722). The analysis of differences between baseline CTP and CTP3m showed a significant reduction of all CTPp (p<0,001), including MTT (p= 0,001). PET/CT response resulted statistically correlated to reduction of all CTPp both at 3 weeks and at 3 months after the end of RCT, except for MTT (p=0,998 and 0,692). At the multivariate analysis the PS was the only parameter that maintain a statistical significance at CTP3m (p=0,037) with a significant trend also at CTP3w(p=0,099).
Conclusion:
The induced damage on the intratumor microvascularization and low resistance flow of neoplastic vessels, explain the decrease of BV and BF whereas the reduction of neoangiogenesis phenomenon could explain the observed decrease of PS.Despite poor sample size, our preliminary results seem to be promising for a potential role of CTP to predict tumor response. PS seems the most valuable to predict the FDG-PET/CT tumor response. Due to the small sample size and short follow up, our results need to be confirmed in other series. Both funcional and morphological datas of the CTP can be usefull in order to reduce as much as possible the rate of false positive.
EP-1105 Impact of waiting time for treatment initation on glotic T1N0M0 cancer radiotherapy results
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